Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 114
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) | ||
| NCT07139782 | Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial | ||
| NCT05263700 | FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary | ||
| NCT01486459 | A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer | ||
| NCT03302728 | Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma | ||
| NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy | ||
| NCT04534725 | COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; | ||
| NCT03806764 | Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient | ||
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | ||
| NCT07090369 | Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer | ||
| NCT07434180 | Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary | ||
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer | ||
| NCT07241715 | Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) | ||
| NCT02999893 | A Study of APR-246 in Oesophageal Cancer | ||
| NCT06510699 | Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial | ||
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE | ||
| NCT05184790 | LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology | ||
| NCT00422864 | A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer | ||
| NCT01716364 | Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome | ||
| NCT06105411 | Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions | ||
| NCT05196789 | Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) | ||
| NCT07213076 | Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib. | ||
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) | ||
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer | ||
| NCT03363867 | BEACON - ABC in Recurrent Platinum Resistant HGSOC | ||
| NCT02506556 | Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer | ||
| NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma | ||
| NCT00753727 | Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma | ||
| NCT02303366 | Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 | ||
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma | ||
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | ||
| NCT00193934 | Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer | ||
| NCT04918810 | Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer | ||
| NCT06279260 | National Robotics-Assisted Radical Prostatectomy Database | ||
| NCT05560659 | Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy | ||
| NCT03287427 | MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial | ||
| NCT04343885 | In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | ||
| NCT07138222 | IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma | ||
| NCT03464942 | Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer | ||
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer | ||
| NCT05864742 | Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | ||
| NCT02468687 | NMP in Relapsed / Refractory Myeloma | ||
| NCT05053854 | PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | ||
| NCT00581880 | Measuring Hope and Hopelessness in Cancer | ||
| NCT02662062 | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer | ||
| NCT01500538 | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | ||
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma | ||
| NCT06082128 | FOCUSau: A Dyadic Digital Health Intervention to Improve the Wellbeing of People With Advanced Cancer and Their Carers | ||
| NCT03161756 | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma | ||
| NCT05154162 | PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI |
